Catalogo Articoli (Spogli Riviste)

OPAC HELP

Titolo:
Dopamine D-3 receptor as a therapeutic target for antipsychotic and antiparkinsonian drugs
Autore:
Joyce, JN;
Indirizzi:
Sun Hlth Res Inst, Thomas H Christopher Ctr Parkinson Dis Res, Sun City, AZ 85351 USA Sun Hlth Res Inst Sun City AZ USA 85351 n Dis Res, Sun City, AZ 85351 USA
Titolo Testata:
PHARMACOLOGY & THERAPEUTICS
fascicolo: 2-3, volume: 90, anno: 2001,
pagine: 231 - 259
SICI:
0163-7258(200105/06)90:2-3<231:DDRAAT>2.0.ZU;2-N
Fonte:
ISI
Lingua:
ENG
Soggetto:
POSITRON EMISSION TOMOGRAPHY; MESSENGER-RNA EXPRESSION; RAT STRIATAL NEURONS; HAMSTER OVARY CELLS; CENTRAL PATHOPHYSIOLOGICAL MECHANISMS; INSITU HYBRIDIZATION HISTOCHEMISTRY; IDIOPATHIC PARKINSONS-DISEASE; CHRONIC HALOPERIDOL TREATMENT; LEVODOPA-INDUCED TOXICITY; TREATED COMMON MARMOSETS;
Keywords:
striatum; caudate putamen; nucleus accumbens; Islands of Calleja; limbic;
Tipo documento:
Review
Natura:
Periodico
Settore Disciplinare:
Life Sciences
Citazioni:
273
Recensione:
Indirizzi per estratti:
Indirizzo: Joyce, JN Sun Hlth Res Inst, Thomas H Christopher Ctr Parkinson Dis Res, 10515 W Santa Fe Dr, Sun City, AZ 85351 USA Sun Hlth Res Inst 10515 W Santa Fe Dr Sun City AZ USA 85351 USA
Citazione:
J.N. Joyce, "Dopamine D-3 receptor as a therapeutic target for antipsychotic and antiparkinsonian drugs", PHARM THERA, 90(2-3), 2001, pp. 231-259

Abstract

The cloning of the gene for the D-3 receptor and subsequent identificationof its distribution in brain and pharmacology allowed for serious consideration of the possibility that it might be a target for drugs used to treat schizophrenia and Parkinson's disease (PD). That is because it is highly expressed in limbic regions of the brain, exhibits low expression in motor divisions, and has pharmacologic similarity to the D-2 receptor. Thus, antipsychotics that were presumed to block D-2 receptors also had high affinity for the D-3 receptor. Dopamine agonists used to treat the clinical symptoms of PD also have high affinity for the D-3 receptor, and two D-3 receptor-preferring agonists were found to be effective for treatment of PD. Many compounds achieving high potency and selectivity are now available, but few have reached clinical testing. Recent findings with respect to the anatomy of this receptor in human brain, altered expression in schizophrenia and PD, and biological models to study its function support the proposal that it is a target for development of drugs to alleviate symptoms in neuropsychiatricand neurologic disorders. Because of distinct aspects of regulation of theD-3 receptor, it represents a unique target for therapeutic intervention in schizophrenia without high potential for unintended side effects such as tardive dyskinesia. It may also be that D-3 receptor agonists can provide neuroprotective effects in PD and can modify clinical symptoms that D-2 receptor-preferring agonists cannot provide. (C) 2001 Elsevier Science Inc. Allrights reserved.

ASDD Area Sistemi Dipartimentali e Documentali, Università di Bologna, Catalogo delle riviste ed altri periodici
Documento generato il 21/09/20 alle ore 06:24:07